| Thursday | |
| 08.00 – 10.00 | OSBREAC/Network board meeting |
| 10.00 – 10.15 | Registration/coffee, tea, fruit |
| liquid biopsy (Moderator Oddmund Nordgård) | |
| 10.15 – 11.00 | Dentist Olaf Aase and wife memorial lecture
Clinical utility of ctDNA in breast cancer: Are we there yet? Invited speaker Isaac Garcia-Murillas, Senior Scientific Officer, Division of Breast Cancer Research, Institute of Cancer Research, London. |
| 11.00 – 11.20 | Liquid biopsy update from Stavanger
Kjersti Tjensvoll, PhD, Stavanger University hospital |
| 11.20 – 11.30 | Short break |
| 11.30 – 11.50 | Breast cancer diagnostics and patient monitoring from biofluid metabolic profiling
Guro F. Giskeødegård, NTNU |
| 11.50 – 12.10 | EU/Transcan project abnormal DNA methylation in cfDNA for early diagnostics
Jovana Klajic, Akershus University Hospital |
| 12.10 – 12.30 | Can we distinguish between selection and neutral evolution from observed data?
Ole Christian Lingjærde, UiO |
| 12.30 – 13.30 | Lunch |
| Treatment and oncology (Moderator Gunnar Mellgren) | |
| 13.30– 14.15 | Vestteknikk lecture
Prognostic and predictive biomarkers in DCIS: HER2, ER expression and multi-clonality of ER expression in the UK/ANZ DCIS trial. Invited speaker Mangesh Thorat; Deputy Director (Clinical) – Barts Clinical Trials Unit at the Wolfson Institute of Preventive Medicine, London. |
| 14.15 – 14.35 | Prognostic value of immune infiltration in breast cancer On behalf of Xavier Tekpli (Thomas Fleischer), Department of Cancer Genetics, Oslo University Hospital |
| 14.35 – 14.45 | Short break |
| 14.45 – 15.05 | Protein profile in neoadjuvant treatment of BC
Mads Haugland Haugen, Department of Tumorbiology, Oslo University Hospital |
| 15.05—15.25 | Lytiske peptider Gunhild Mælandsmo, Department of Tumorbiology, Oslo University Hospital |
| 15.25—15.45 | Glutaminase inhibition in PDX models of breast cancer Siver A. Moestue, NTNU |
| 16.00 – 17.00 | Sola Strand walk |
| 17.00 – 17.20 | Emit Bjørn Naume, Oslo University Hospital |
| 17.20 – 17.40 | Studies in Vestre Viken Kristine Kleivi Sahlberg, Vestre Viken |
| 17.40 – 18.00 | Next generation sequencing studies Torben Luders, Akershus University Hospital |
| 18.00 – 18.10 | PBCB update Siri Lunde, Stavanger University Hospital |
| 18.10 – 18.30 | Petramac Hans Petter Eikesdal, Helse Bergen |
| 19.00 | Dinner |
| Friday | |
| Prevention and early diagnosis (Moderator ) | |
| 08.30– 08.50 | SRC-2-dependent regulation of epithelial-mesenchymal transition in breast cancer cells. Gunnar Mellgren, Hormone Laboratory, Haukeland University hospital |
| 08.50 – 09.10 | Ductal Carcinoma In Situ – a pre-invasive lesion subject to overtreatment Therese Sørlie Department of Cancer Genetics, Oslo University Hospital |
| 09.10 – 09.30 | Therapeutic strategies against Resistant and Metastatic Breast Cancer (TheraMetBC). Gunhild Mælandsmo, Department of Tumor Biology, Oslo University Hospital |
| 09.30 – 09.50 | From tumor microstructure to MRI contrast Tone F. Bathen, NTNU
|
| 10.00 – 10.30 | Break |
| 10.30 – 10.50 | “Percathe” Horizon 2020 application Thomas Fleischer, Oslo University Hospital |
| 10.50 — 11.10 | Biomarkers in triple negative breast cancer + ICART collaboration
Emiel Janssen, Stavanger University Hospital |
| 11.10 – 11.30 | |
| 11.30 – 12.30 | Lunch |
| Panel debate Moderator Kristine Kleivi/Bjørn Naume | |
| 12.30 – 13.45 | “Further plans for the network”. Panel debate about national clinical studies (the new neoadjuvant study (petremac2, EMIT), setting up a national biobank and standardization of the biobanks available now, more collaboration on bio-informatics. |
| 13.45 – 13.55 | Short break for setting up the speed up dates |
| Speed updates (6 speakers, 10 min each) | |
| 14.00 – 15.00 | 1. Proliferation and tamoxifen resistance Nina Gran Egeland, Stavanger
2. Serum metabolomics-based patient monitoring in the NeoAva study Julia Debik, NTNU 3. Non-coding molecular markers and mechanisms Miriam R Aure, Department of Cancer Genetics, Oslo University Hospital 4. Can miRNAs improve HER2+ BC treatment in vitro Lisa Gregusson Svartdal, Vestre Viken/Department of Tumorbiology, Oslo University Hospital
|
| 15.00- – 15.10 | Short break |
| 15.10 – 15.30 | Award for best speed update and conclusions |
